Abstract
We investigated the impact of renal impairment (RI) on the outcome in multiple myeloma (MM) patients following induction and autologous stem cell transplantation (ASCT). Among 349 patients who received a first ASCT for MM, 86 (24.6%) had RI at diagnosis, defined as estimation of glomerular filtration rate (eGFR) <40 mL/min/1.73 m2 according to the modification of diet in renal disease (MDRD) formula. Post induction reversal of renal function occurred in 68 (79%) patients including complete renal response in 37.2%. Two hundred and fifty-one patients had received novel agents for induction; posttransplant complete response (CR) rates were 71.4% for patients with renal impairment (RI) versus 67.2% in those without RI, p = 0.23. The quality of stem cell collection and days to engraftment were similar except that patients with RI required higher transfusion numbers of packed red cells (p < 0.002) and platelets (p < 0.007). The median overall survival (OS) was 96 months (95% confidence interval [CI] 72.80–119.20) for patients with eGFR ≥40 mL/min, n = 195) versus 62 months (95% CI 28.7–95.3) for 56 patients with RI (eGFR <40 mL/min), p = 0.15. The 5-year OS was 64.6% versus 54.4%, respectively. The median progression-free survival (PFS) was 52 months (95% CI 36.3–67.7) for patients with eGFR ≥40 mL/min versus “not reached” for those with eGFR <40 mL/min p = 0.87; and the 5-year PFS was 48.1% versus 51%, respectively. We conclude that induction with novel agents results in reversal of renal dysfunction in the majority of patients. Consolidation with Hemopoietic Stem Cell Transplantation (HSCT) overcomes the adverse impact of RI on survival.
Article PDF
Avoid common mistakes on your manuscript.
References
Durie, BG, Salmon, SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36;842–54.
Brighten, S, Mateos, MV, Zweegman, S, Larocca, A, Falcone, AP, Oriol, A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 2013;98;980–7.
Alexanian, R, Barlogie, B, Dixon, D. Renal failure in multiple myeloma. Arch Intern Med 1990;150;1693–5.
Levey, AS, Stevens, LA, Schmid, CH, Zhang, YL, Castro 3rd, AF, Feldman, HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150;604–12.
Dimopoulos, MA, Sonneveld,P, Leung, N,Merlini, G, Ludwig, H, Kastritis, E, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016;34;1544–57.
Gonsalves, WI, Leung, N, Rajkumar, SV, Dispenzieri, A, Lacy, MQ, Hayman, SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 2015;5;e296.
Kastritis, E, Anagnostopoulos, A, Roussou, M, Gika, D, Matsouka, C, Barmparousi, D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007;92;546–9.
Roussou, M, Kastritis, E, Christoulas, D, Migkou, M, Gavriatopoulou, M, Grapsa, I, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34;1395–7.
Dimopoulos, MA, Delimpasi, S, Katodritou, E, Vassou, A, Kyrtsonis, MC, Repousis, P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014;25;195–200.
Dimopoulos, MA, Cheung, MC, Roussel, M, Liu, T, Gamberi, B, Kolb, B, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica 2016;101; 363–70.
Chakraborty, R, Muchtar, E, Kumar, S, Buadi, FK, Dingli, D, Dispenzieri, A. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant 2017;52;34–40.
San Miguel, JF, Lahuerta, JJ, García-Sanz, R, Alegre, A, Bladé, J, Martinez, R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1;28–36.
Bird, JM, Fuge, R, Sirohi, B, Apperley, JF, Hunter, A, Snowden, J, et al. British society of blood and marrow transplantation. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. Br J Haematol 2006;134; 385–90.
Lee, CK, Zangari, M, Barlogie, B, Fassas, A, van Rhee, F, Thertulien, R, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33; 823–8.
Knudsen, LM, Nielsen, B,Gimsing, P, Geisler, C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005;75;27–33.
Gertz, MA, Lacy, MQ, Dispenzieri, A, Hayman, SR, Kumar, S, Leung, N, Gastineau, DA. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007;39;605–11.
St Bernard, R, Chodirker, L, Masih-Khan, E, Jiang, H, Franke, N, Kukreti, V, Tiedemann, R, Trudel, S, Reece, D, Chen, CI. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 2015;50;95–9.
Khan, R, Apewokin, S, Grazziutti, M, Yaccoby, S, Epstein, J, van Rhee, F, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia 2015;29;1195–201.
Sweiss, K, Patel, S, Culos, K, Oh, A, Rondelli, D, Patel, P. Melphalan 200 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 2016;51; 1337–41.
Waszczuk-Gajda, A, Lewandowski, Z, Drozd-Sokołowska, J, Boguradzki, P, Dybko, J, Wróbel, T, et al. Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients-DAUTOS study of the Polish Myeloma Study Group. Eur J Haematol 2018;101;475–85.
Augeul-Meunier, K, Chretien, ML, Stoppa, AM, Karlin, L, Benboubker, L, Diaz, JMT, et al. Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Bone Marrow Transplant 2018;53;749–55.
MDRD GFR Equation. https://www.mdcalc.com/mdrd-gfr-equation (accessed May 31, 2019).
Kumar, L, Boya, RR, Pai, R, Harish, P, Mookerjee, A, Sainath, B, et al. Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J India 2016;29;192–9.
Bladé, J, Samson, D, Reece, D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102;1115–23.
Ludwig, H, Adam, Z, Hajek, R, Greil, R, Tathova, E, Keil, F, et al. light chain induced acute renal failure can be reversed by bortezomib, doxorubicin and dexamethasone in multiple myeloma. Results of a phase II study. J Clin Oncol 2010;28; 4635–41.
Bhowmik, D, Yadav, S, Kumar, L, Agarwal, S, Agarwal, SK, Gupta, S. Sequential autologous hematopoietic stem cell transplant followed by renal transplant in multiple myeloma. Ind J nephrology 2017;27;324–6.
Greipp, PR, San Miguel, J, Durie, BG, Crowley, JJ, Barlogie, B, Bladé, J, et al. International staging system for multiple myeloma. J Clin Oncology 2005;23;3412–20.
Yadav, P, Cook, M, Cockwell, P. Current trends of renal impairment in multiple myeloma. Kidney Dis 2015;1;241–57.
Antlanger, M, Dust, T, Reiter, T, Böhm, A, Lamm, WW, Gornicec, M, et al. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer 2018; 18;1008.
Glavey, SV, Gertz, MA, Dispenzieri, A, Kumar, S, Buadi, F, Lacy, M. Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplant 2013;48;1543–7.
Tamaki, M, Nakasone, H, Gomyo, A, Hayakawa, J, Akahoshi, Y, Harada, N, et al. Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan. Int J Hematol 2018;108;423–31.
Grazziutti, ML, Dong, L, Miceli, MH, Krishna, SG, Kiwan, E, Syed, N, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006;38;501–6.
Knudsen, LM, Hjorth, M, Hippe, E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65;175–81.
Badros, A, Barlogie, B, Siegel, E, Roberts, J, Langmaid, C, Zangari, M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114;822–9.
Mahindra, A, Hari, P, Fraser, R, Fei, M, Huang, J, Berdeja, J, et al. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant 2017;52;1616–22.
Shaw, PJ, Nath, CE, Lazarus, HM. Not too little, not too much-just right! (Better ways to give high dose melphalan). Bone Marrow Transplant 2014;49;1457–65.
Scheid, C, Sonneveld, P, Schmidt-Wolf, IG, van der Holt, B, el Jarari, L, Bertsch, U, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 2014;99;148–54.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Data availability statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Kumar, L., Kumar Chellapuram, S., Dev, R. et al. Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma. Clin Hematol Int 1, 205–219 (2019). https://doi.org/10.2991/chi.d.190805.003
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.190805.003